Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome

16 Mar 2022

Abstract excerpt

Immune checkpoint inhibitors (ICI) represented a step forward in improving the outcome of patients with various refractory solid tumors and several therapeutic regimens incorporating ICI have already been approved for a variety of tumor entities. However, besides remarkable long-term responses, checkpoint inhibition can trigger severe immune-related adverse events in some patients. In order to improve safety of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35328630
DOI: 10.3390/ijms23063207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival OutcomePMID 35328630Read ↗

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious DiseasesSemantic proximity Read ↗

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitorsSemantic proximity Read ↗

CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell TherapySemantic proximity Read ↗

The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic ImplicationsSemantic proximity Read ↗

CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applicationsSemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapySemantic proximity Read ↗

T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cellsSemantic proximity Read ↗

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editingSemantic proximity Read ↗

Cancer Immunotherapy: A Focus on the Regulation of Immune CheckpointsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.